Karim Elakabawi

The Incidence of Contrast-induced Acute Kidney Injury in Patients on Dapagliflozin Undergoing Percutaneous Coronary Interventions

Hany Hassan Ebaid, Ahmed Bahaa El Dein Abd El Hafeez, Khaled Emad El Dein El Rabat & Karim Elakabawi · Cardiology and Angiology: An International Journal · 2024

Background: Sodium glucose cotransporter 2 receptor inhibitor (SGLT2i) dapagliflozin protects the renal function of individuals with coronary artery disease (CAD) and reduces incidence of contrast-induced acute kidney injury (CI-AKI) among individuals having percutaneous coronary...

Open access Research Article 10.9734/ca/2024/v13i4454

The New Relationship between Kawasaki Disease and MIS-C

Fuyong Jiao, Xiaojin Ding, Haotian Xu, Karim Elakabawi, Ho-Chang Kuo & Jiale Wang · International Journal of TROPICAL DISEASE & Health · 2022

Kawasaki disease (KD) is a childhood disease associated with serious coronary artery complications. It is the most common cause of pediatric acquired heart disease in developed countries and is increasingly reported from many developing countries. The etiology of KD is still unce...

Open access Research Article 10.9734/ijtdh/2022/v43i730600